DXCM
stock Healthcare Medical DevicesOverall Healthy · 64%
- Fundamentals Strong
- Trajectory Climbing
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 4 of 5 trend signals bullishRSI 64 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $72.77
- -0.93%
- Close
- $72.77
- -0.93%
- Current
- $72.77
- Prev close
- $73.45
- Today
- 3.73M
- 3-mo avg
- 5.20M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 3082 days ago
- Next expected
- Jul 29in 8 days
Recent earnings dates
- Apr 30 82 days ago
- Feb 12 159 days ago
- Jan 12 190 days ago
- Oct 30, 2025 264 days ago
Past earnings dates come from DXCM’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), DXCM’s fundamentals read as strong overall.
At 31.2x, investors are paying up; a fair amount of future growth is already in the price.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 17.9% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 30.5% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 13.2% return on assets is strong; the company squeezes good profit from its assets.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 1.31, the company carries a moderate, manageable amount of debt.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.88, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 15.6% from the prior year: strong top-line expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 45.1% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Net income | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Diluted EPS | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
| Dividend / share | — | — | — | — | — |
| Total assets | $4.9B | $5.4B | $6.3B | $6.5B | $6.3B |
| Total liabilities | $2.9B | $3.3B | $4.2B | $4.4B | $3.6B |
| Shareholder equity | $2.0B | $2.1B | $2.1B | $2.1B | $2.7B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $994.2M | $1.1B | $1.0B | $1.2B | $1.2B | $1.3B | $1.2B |
| Net income | $143.5M | $134.6M | $151.7M | $105.4M | $179.8M | $283.8M | $267.3M | $199.5M |
| Diluted EPS | $0.35 | $0.34 | $0.37 | $0.27 | $0.45 | $0.70 | $0.67 | $0.51 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 57d ago
- Brown Michael Jon EVP, Chief Legal Officer
- Sayer Kevin R Executive Chair · Director
- Sylvain Jereme M EVP, Chief Financal Officer
- Altman Steven R Director
- Augustinos Nicholas Director
- Collins Richard Alexander Director
- Foletta Mark G Director
- Heller Bridgette P Director
Officers and board are drawn from DXCM’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 20 +6.7% one-day move
- May 18 +5.6% one-day move
- May 15 +6.6% one-day move
- Mar 27 −5.8% one-day move
- Mar 2 Officer or director change reported in an 8-K
- Feb 26 Officer or director change reported in an 8-K
- Feb 13 +7.6% one-day move
- Dec 31, 2025 FY2025 net income +45% YoY
- Dec 22, 2025 Officer or director change reported in an 8-K
- Nov 11, 2025 +6.0% one-day move
- Oct 31, 2025 −14.6% one-day move
- Oct 27, 2025 Officer or director change reported in an 8-K
- Oct 10, 2025 New 6-month low (-27% off peak)
- Sep 19, 2025 −11.0% one-day move
- Sep 16, 2025 Officer or director change reported in an 8-K
- Sep 3, 2025 +6.2% one-day move
- Aug 25, 2025 −7.7% one-day move
- Jul 31, 2025 −9.3% one-day move
- Jul 30, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report